ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck 1Q Net Rises 67% On Lower Costs; Sales Growth Slows

DOW JONES NEWSWIRES Merck & Co.'s (MRK) first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth. Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin. Merck has said it expects to seek regulatory approval for five new products this year and in 2013, including potential treatments for osteoporosis, insomnia and a next-generation vaccine against a cancer-causing virus. The drug maker also has been focusing on areas such as hepatitis C and diabetes. Merck reported a profit of $1.74 billion, or 56 cents a share, up from $1.04 billion, or 34 cents, a year earlier. Excluding items such as acquisition-related and restructuring costs, earnings rose to 99 cents from 92 cents. Its March projection was earnings of 95 cents to 98 cents a share, below analysts' expectations at the time. Sales rose 1.3% to $11.73 billion, missing the $11.82 billion forecast from analysts polled by Thomson Reuters. Operating margin rose to 21.4% from 14.9%, reflecting a 14% drop in research and development costs. Pharmaceutical sales grew 2.7% to $10.08 billion. Singulair sales edged up 0.9%, while sales of Vytorin declined 8%. The animal-health business, which includes products for farm animals and pets, posted a 8.3% revenue increase. Sales in the consumer division--which includes over-the-counter allergy medicine Claritin and Coppertone skin-care products--rose 7.2%. Shares closed Thursday at $38.47 and were inactive premarket. The stock is up 2% so far this year. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
05/26/201608:08:00Corporate Social Responsibility Related News Releases and Story...
05/24/201614:35:00Merck Announces Third-Quarter 2016 Dividend
05/24/201613:31:00MSD Animal Health riceve l'approvazione all'immissione in commercio...
05/24/201612:21:00MSD Animal Health erhält Marktzulassung der Europäischen Arzneimittelagentur f...
05/24/201609:20:00MSD Animal Health reçoit une autorisation de commercialisation...
05/24/201608:00:00Merck to Present at the UBS Global Healthcare Conference
05/24/201606:19:00MSD Animal Health Receives Marketing Approval from European Medicines...
05/23/201616:40:00Samsung Targets U.S. Drug Market With Remicade Knockoff
05/23/201609:00:00Merck Foundation Announces the Alliance to Advance Patient-Centered...
05/20/201614:35:51Statement of Changes in Beneficial Ownership (4)
05/19/201616:20:00Germany's Bayer Breaks With Caution in Monsanto Bid
05/18/201622:27:00New Hope for Melanoma Patients -- Update
05/18/201617:29:00New Hope for Melanoma Patients
05/18/201617:19:00New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 & KEYNOTE-001...
05/16/201608:00:00New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting...
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)
05/12/201611:41:25Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad